A New Generation of the Most Accurate Test for QFT Plus builds on the legacy of QuantiFERON TB Gold, which was the third generation version of this important technology that has established itself as a cost effective tool for TB infection testing with more than 20 million tests distributed worldwide since its initial launch.
QFT Plus, which was recently CE IVD marked, is now being made available in Europe and other markets and will gradually replace the use of QuantiFERON TB Gold, which achieved an important milestone with more than $100 million of annual sales in 2014 and becoming one of the largest products within the QIAGEN portfolio. QFT Plus represents a key milestone in the development of diagnostic tests for latent TB infection. For the first time, a diagnostic test offers the ability to capture a much broader picture of an individual's immune response to TB infection. This technological advancement is critical to advancing the understanding of how the immune system reacts to TB infection, and is expected to set a new standard for future disease management. Among the many new features of QFT Plus are: Improved technology that delivers even higher sensitivity (ability to correctly identify those patients with disease) and specificity (ability to correctly identify all patients without disease) in patients at greatest risk for TB infection, particularly individuals co infected with HIV/TB and other immunocompromised patients. Advances to support research into the risk stratification of latent TB infections developing into active disease based burberry outlet online authentic on the first time incorporation of CD8+ T cell response data, which provides valuable new information to researchers by measuring a broader range of immune response. Published scientific evidence underlines the future potential of CD8+ T cells in distinguishing active from latent TB, discerning recent vs. old infections, detecting burberry raincoat TB in certain risk populations (such as HIV co infection and young children), as well as assessing response to TB treatment. Workflow improvements that allow for even more efficient implementation, especially in large scale TB screening programs. These include a single tube blood collection option as well as the ongoing use of the unique "assay in collection tube" design that allows for immediate stimulation of the blood sample, which ensures no loss of T burberry design cell activity that is critical for obtaining accurate and reliable results. Further improvements to test reliability, consistency and performance designed to result in fewer indeterminate results and less requirements for retesting. The launch of QFT Plus coincides with the early stages of implementing the Post 2015 Global Tuberculosis Strategy, which was developed by the World Health Organization (WHO) and made public in October 2014. Overall, a global pool of 2 billion people (or 1 in 3 people worldwide) is estimated to be infected with Mycobacterium tuberculosis, and up to 10% of these patients are expected to develop the active form of this airborne and highly contagious disease during their lifetime. Leading TB control programs are turning to QuantiFERON TB Gold to replace the tuberculin skin test (TST) because this modern test's superior clinical performance and significantly simpler administration improves the cost effectiveness of TB control programs and overall healthcare. The QuantiFERON TB Gold technology is faster, laboratory based and quality controlled, and more accurate than the century old TST testing method. The global rollout of QuantiFERON TB Gold Plus will even further enhance these significant advantages. A costly TB control programs relying on skin tests the high rate of false positives lead to unnecessary evaluation and treatment. studies show that 20 85% of positive TST results are negative in BCG vaccinated persons tested with QFT. False positive results require follow up care such as physical examinations, x rays and laboratory work, even for patients who turn out to have no TB infection adding unnecessarily to patient risk from unneeded treatment and healthcare expenses. Positive readings provided by QuantiFERON TB technology, on the other hand, are up to 99% accurate. QFT Plus is the latest product introduction involving the proprietary QuantiFERON technology, which offers a unique and efficient approach to disease detection. QuantiFERON is able to provide objective information on the activity of cell mediated functions of the immune system by measuring the release of interferon gamma in response to specific antigens or proteins contained in whole blood samples through a simple, highly automated process. QuantiFERON is in particular unique in its ability to detect presymptomatic infections that cannot be discovered using standard diagnostic technologies. In addition to the TB infection tests, QIAGEN also offers a CE version of QuantiFERON CMV, a whole blood assay to monitor changes burberry coat outlet price in cell mediated immunity to cytomegalovirus (CMV), which is the most common and problematic viral infection in solid organ transplant recipients. Additional assays involving QuantiFERON are in development. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue.
Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of September 30, 2014, QIAGEN employed approximately 4,200 people in over 35 locations worldwide.
Prev: burberry happy scarf
Next: clearance burberry bags